A randomised phase III clinical trial investigating the effect of FRAGMin Added to standard Therapy In patients with lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Dalteparin sodium (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer; Small cell lung cancer; Thrombosis
- Focus Therapeutic Use
- Acronyms FRAGMATIC
- 23 Dec 2015 Results published in the Journal of Clinical Oncology
- 29 Oct 2013 Primary endpoint 'Overall-survival' has not been met.
- 29 Oct 2013 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History